Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.

Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C.

Am J Hematol. 2018 Nov;93(11):1394-1401. doi: 10.1002/ajh.25261. Epub 2018 Sep 26.

PMID:
30132965
2.

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C.

Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7.

3.

Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses.

Vaisitti T, Braggio E, Allan JN, Arruga F, Serra S, Zamò A, Tam W, Chadburn A, Furman RR, Deaglio S.

Cancer Res. 2018 Jul 1;78(13):3413-3420. doi: 10.1158/0008-5472.CAN-17-4004. Epub 2018 May 7.

PMID:
29735551
4.

Optimal management of the young patient CLL patient.

Allan JN, Furman RR.

Best Pract Res Clin Haematol. 2018 Mar;31(1):73-82. doi: 10.1016/j.beha.2017.10.012. Epub 2017 Nov 20. Review.

PMID:
29452669
5.

Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor.

Vaisitti T, Gaudino F, Ouk S, Moscvin M, Vitale N, Serra S, Arruga F, Zakrzewski JL, Liou HC, Allan JN, Furman RR, Deaglio S.

Haematologica. 2017 Nov;102(11):1878-1889. doi: 10.3324/haematol.2017.173419. Epub 2017 Aug 31.

6.

CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.

Allan JN, Roboz GJ, Askin G, Ritchie E, Scandura J, Christos P, Hassane DC, Guzman ML.

Leuk Lymphoma. 2018 Apr;59(4):821-828. doi: 10.1080/10428194.2017.1352089. Epub 2017 Jul 18.

7.

Association of Ibrutinib Treatment With Bleeding Complications in Cutaneous Surgery.

Parra CE, Newsom E, Lee EH, Allan JN, Minkis K.

JAMA Dermatol. 2017 Oct 1;153(10):1069-1070. doi: 10.1001/jamadermatol.2017.1877. No abstract available.

PMID:
28700792
8.

Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N.

Allan JN, Friedman KD, DeSancho MT.

Int J Hematol. 2014 Dec;100(6):602-6. doi: 10.1007/s12185-014-1662-3. Epub 2014 Sep 12.

PMID:
25212677
9.

Concise review: Leukemia stem cells in personalized medicine.

Guzman ML, Allan JN.

Stem Cells. 2014 Apr;32(4):844-51. doi: 10.1002/stem.1597. Review.

Supplemental Content

Loading ...
Support Center